Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor

Journal of Korean Medical Science

Volumn 28, Issue 10, 2013, Pages 1443-1448

  Yang, Hongxin ^a,b   Shen, Chaoyong ^a   Zhang, Bo ^a   Chen, Haining ^a   Chen, Zhixin ^a   Chen, Jiaping ^a  

^a SICHUAN UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CD9; Gastric stromal tumor; Gastrointestinal stromal tumors; Immunohistochemistry; Prognosis

Indexed keywords

CD9 ANTIGEN;

ADULT; AGED; ARTICLE; CD9; DISEASE FREE SURVIVAL; FEMALE; GASTRIC STROMAL TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY;

CD9; GASTRIC STROMAL TUMOR; GASTROINTESTINAL STROMAL TUMORS; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD9; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84885793903     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.10.1443     Document Type: Article

References (22)

1. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9.
2. Buim ME, Lourenço SV, Carvalho KC, Cardim R, Pereira C, Carvalho AL, Fregnani JH, Soares FA. Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol 2010; 46: 166-71.
3. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T, Fujita N. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 2008; 112: 1730-9.
4. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10: 4109-17.
5. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-41.
6. Hassan I, You YN, Shyyan R, Dozois EJ, Smyrk TC, Okuno SH, Schleck CD, Hodge DO, Donohue JH. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15: 52-9.
7. Kang YK, Kim KM, Sohn T, Choi D, Kang HJ, Ryu MH, Kim WH, Yang HK. Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci 2010; 25: 1543-52.
8. Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, Trent JC. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67: S15-24.
9. Breiner JA, Meis-Kindblom J, Kindblom LG, McComb E, Liu J, Nelson M, Bridge JA. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet 2000; 120: 111-6.
10. Chen Y, Liou CP, Tseng HH, Jan YJ, Li CF, Tzeng CC. Deletions of chromosome 1p and 15q are associated with aggressiveness of gastrointestinal stromal tumors. J Formos Med Assoc 2009; 108: 28-37.
11. Yang J, Du X, Lazar AJ, Pollock R, Hunt K, Chen K, Hao X, Trent J, Zhang W. Genetic aberrations of gastrointestinal stromal tumors. Cancer 2008; 113: 1532-43.
12. Okamoto Y, Sawaki A, Ito S, Nishida T, Takahashi T, Toyota M, Suzuki H, Shinomura Y, Takeuchi I, Shinjo K, et al. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour. Gut 2012; 61: 392-401.
13. Huang CL, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H, Ueno M, Miyake M. MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene 2004; 23: 7475-83.
14. Imhof I, Gasper WJ, Derynck R. Association of tetraspanin CD9 with transmembrane TGF{alpha} confers alterations in cell-surface presentation of TGF{alpha} and cytoskeletal organization. J Cell Sci 2008; 121: 2265-74.
15. Saito Y, Tachibana I, Takeda Y, Yamane H, He P, Suzuki M, Minami S, Kijima T, Yoshida M, Kumagai T, et al. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res 2006; 66: 9557-65.
16. Soyuer S, Soyuer I, Unal D, Ucar K, Yildiz OG, Orhan O. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract 2010; 206: 607-10.
17. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R, Nagatomo I, Takeda Y, Kida H, Goya S, et al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 2010; 70: 8025-35.
18. Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 2003; 98: 1649-57.
19. Setoguchi T, Kikuchi H, Yamamoto M, Baba M, Ohta M, Kamiya K, Tanaka T, Baba S, Goto-Inoue N, Setou M, et al. Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors. Cancer Sci 2011; 102: 883-9.
20. Fan J, Zhu GZ, Niles RM. Expression and function of CD9 in melanoma cells. Mol Carcinog 2010; 49: 85-93.
21. Zou Q, Xiong L, Yang Z, Lv F, Yang L, Miao X. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol 2012; 10: 92.
22. Zöller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009; 9: 40-55.